External broker reports(aggregated public sources), Mirae Asset Securities

Mirae Asset Securities

External broker reports(aggregated public sources)

Leading full-service brokerage firm in Vietnam. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>For 3Q25, Samsung C&amp;T reported consolidated revenue of W10.2tr (-1.5% YoY) and operating profit of W993.4bn (+35% YoY), with the latter beating the consensus (W791.9bn) by 25%.</li><li>On the same day, Samsung Biologics announced consolidated operating profit that exceeded the consensus by 26%, or approximately W150bn; excluding this, we believe Samsung C&amp;T’s operating profit was 6% above the consensus.</li><li>The operating profit contribution of the biologics group increased to around 73% in the quarter, driven by the full operation of Plant 4 and milestone income. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

For 3Q25, Samsung C&amp;T reported consolidated revenue of W10.2tr (-1.5% YoY) and operating profit of W993.4bn (+35% YoY), with the latter beating the consensus (W791.9bn) by 25%.On the same day, Samsung Biologics announced consolidated operating profit that exceeded the consensus by 26%, or approximately W150bn; excluding this, we believe Samsung C&amp;T’s operating profit was 6% above the consensus.The operating profit contribution of the biologics group increased to around 73% in the quarter, driven by the full operation of Plant 4 and milestone income. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Samsung C&T  (028260 KS/Buy)Biologics Business Accounts for 73% of Operating Profit

South Korea

Samsung C&T Corporation conducts diversified business support services and resort operation activities. The Company offers a range of services in areas including clothing retail, construction, energy, real estate, food service, and resort accommodations. Samsung C&T also operates a resort with amusement rides, a zoo, water park, golf clubs, and restaurants.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Samsung C&T (028260 KS)

Samsung C&T (028260 KS/Buy)Biologics Business Accounts for 73% of Operating Profit

For 3Q25, Samsung C&T reported consolidated revenue of W10.2tr (-1.5% YoY) and operating profit of W993.4bn (+35% YoY), with the latter beating the...

Mirae Asset Securities

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)